NYSE:UNH

UnitedHealth Group Inc (UNH)

395.62
-6.11 (1.52%)
as of Aug 17, 2026, 8:00:00 pm Market Open.
289 watching
0
Investor Insights
star iconAug 16, 2026, 12:00 am

This summary was created by AI, based on 36 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) has seen a tumultuous year, with many experts highlighting the volatility stemming from changes in leadership, regulatory pressures, and rising medical costs. Positive reviews point to regaining earnings power, especially with the return of the former CEO, who is expected to manage costs effectively and steer the company towards recovery. However, there are significant concerns about the impact of government regulations and Medicare adjustments, which could pressure margins and complicate growth prospects. The consensus reflects a blend of optimism for long-term recovery juxtaposed with caution due to ongoing industry challenges and political uncertainties. In summary, while there are indicators of potential upside, the unpredictable nature of healthcare reforms in the U.S. builds a case for cautious investment.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Fair Value
review icon
Similar
Cvs, CVS
BUY

Likes it. It's a compounder. Low unemployment is a catalyst for health. Medicare has been strong

BUY

Falling after earnings, though beat revenues and EPS and raised guidance. Are the cream of the crop in healthcare services. The fall comes from the lighter-than-expected guide, and they had a nice ride in recent weeks.

BUY ON WEAKNESS

They rallied into today's earnings. Though client acquisition has stagnated, their crossover business has grown revenues. He welcomes today's weakness, so he can add shares.

TOP PICK

Insurance for employers and individuals in the USA.
Overhang on the stock fading.
Has owned shares for a long time.
Believes prospects for business excellent.

BUY

The most consistent beat-and-raise company on the Dow. Add shares ahead of their Friday report.

DON'T BUY
Caller works at a health facility where UNH is rejecting claims from a significant number of patients

That news is distressing. That's unfair. He switched to Humana for coverage, but also bought Humana shares.

BUY

She just added shares. It's been underperforming the market, but still has growth being #1 in health insurance in the U.S. Will enjoy earnings growth this year whatever happenings to the economy.

BUY

Like Pepsi, it's a steady earner and trades at the same 21x PE. Lots of cash flow and higher ROE than peers. Will do well in a tough economy.

TOP PICK

Defensive stock that is good for long term investors.
Likes dynamics of healthcare industry - believes demand for healthcare will remain strong.
Very well run company.
Don’t think this operates in Canada
Continually growing business.

BUY

Strong sector with demand for healthcare services excellent.
Largest health insurance provider in USA (within sector).
130 million customers in the USA.
Aging population creating demand for health insurance. 
Good for the long term investor. 
Would recommend buying. 

HOLD

He trimmed it last September to decrease his overall healthcare allocation. UNH has slowing topline and profits, but it's still growing with secular tailwinds, and rising enrollments, so he's holding on. UNH has outperformed all healthcare over the last 12 months by 40%.

DON'T BUY

It provides health care and healthcare insurance products. It is difficult to understand and is just one bad news headline away from destroying its business. He prefers to stay away from Healthcare and has only one - Stryker.

HOLD
He looks for strong growth, cashflows, and stability. He owns, and would recommend looking at.
BUY
The U.S. Healthcare sector is a good place to be. He prefers CVS but UNH is also excellent. More money is spent on healthcare in the U.S. than anywhere else in the world.
BUY
Allan Tong’s Discover Picks UNH is a one-stop shop for health in America by operating insurance, pharmacies and clinics. If there is a caveat, it’s that possible UNH stock has enjoyed too much of a run lately. However, since Boxing Day have retraced from $530 to $489. The street has 11 buys and three holds at a $602.64 price target which is 23% higher than now. Read 3 Defensive Stocks to Catch the Rebound for our full analysis.
Showing 121 to 135 of 290 entries